Centre for Epidemiology Versus Arthritis
- Research works
- 21 fractional, all time
- Citations
- 99 4.7 per fractional work
- Top-10% rate
- 8.6% record average 16.5%
- Open access
- 86% world 28%
Not ranked overall: Centre for Epidemiology Versus Arthritis is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Medicine, 4.0×. Every wedge is a field page.
Which keywords describe research at Centre for Epidemiology Versus Arthritis?
By fractional works in all years, weighted toward what it does more of than the world: Autoantibodies, Inflammation, Rheumatoid Arthritis, Cytokines, Cardiovascular Risk, Biological Therapy, Disease-Modifying Antirheumatic Drugs and Antiphospholipid Syndrome.
- Juvenile Idiopathic Arthritis
- Systemic Lupus Erythematosus
- Antiphospholipid Syndrome
- Epidemiology
- Biological Therapy
- Cardiovascular Risk
- Inflammation
- Autoantibodies
- Rheumatoid Arthritis
- Cytokines
- Disease-Modifying Antirheumatic Drugs
- Quality of Life
- Primary Care
- Rituximab
Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 14 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 14 words, with their numbers
- Autoantibodies5▲ 105×5 topics
- Inflammation5▲ 9.6×14 topics
- Rheumatoid Arthritis4▲ 187×2 topics
- Cardiovascular Risk4▲ 51×2 topics
- Cytokines4▲ 67×2 topics
- Biological Therapy4▲ 320×1 topic
- Disease-Modifying Antirheumatic Drugs4▲ 365×1 topic
- Epidemiology2▲ 2.5×16 topics
- Quality of Life2▲ 5.4×4 topics
- Antiphospholipid Syndrome1▲ 121×1 topic
- Primary Care1▲ 14×6 topics
- Systemic Lupus Erythematosus1▲ 110×1 topic
- Rituximab1▲ 33×3 topics
- Juvenile Idiopathic Arthritis1▲ 97×2 topics
Which research topics does Centre for Epidemiology Versus Arthritis publish most on?
By volume in 2022–2025: Rheumatoid Arthritis Research and Therapies, Spondyloarthritis Studies and Treatments, Systemic Lupus Erythematosus Research and Autoimmune and Inflammatory Disorders Research.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Rheumatoid Arthritis Research and Therapies Rheumatology 2 works
- 2 Spondyloarthritis Studies and Treatments Rheumatology 1 works
- 3 Systemic Lupus Erythematosus Research Rheumatology 1 works
- 4 Autoimmune and Inflammatory Disorders Research Hematology 1 works
- 5 Opioid Use Disorder Treatment Public Health, Environmental and Occupational Health 1 works
- 6 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 0 works
- 7 Musculoskeletal Disorders and Rehabilitation Rehabilitation 0 works
- 8 Adolescent and Pediatric Healthcare Speech and Hearing 0 works
- 9 Workplace Health and Well-being General Health Professions 0 works
- 10 Fibromyalgia and Chronic Fatigue Syndrome Research Psychiatry and Mental health 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Centre for Epidemiology Versus Arthritis's research output changed?
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Manchester
- University of Manchester
- Manchester Metropolitan University
- Manchester Royal Infirmary
- Manchester Academic Health Science Centre
- The Christie Hospital
- Manchester University NHS Foundation Trust
- Cancer Research UK Manchester Institute
- Wythenshawe Hospital
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.